![](https://investorshub.advfn.com/uicon/33511.png?cb=1696427377)
Saturday, September 26, 2015 8:51:49 PM
But you are correct. Multiple Ph. 2 candidates, CLIA for LymPro and MS Precise, as well as ESS test trials and Eltopa results, all in 4Q15, along with an NASDAQ up listing, will make this a double digit stock rather quickly.
My concern at present is with AMBS's balance sheet and declining shareprice. These have only contributed to up listing from weakness. I suspect the NASDAQ is reviewing these issues as well. If they obtain significant non-dilutive funding, or strike a sizeable JV Partnership prior to up listing, I believe it will "grease the skids" so to speak for NASDAQ to make their final ruling in favor of AMBS.
Contrarily, if AMBS recieves the nod from the NASDAQ before obtaining significant non-dilutive financing, or striking a sizeable JV Partnership, then its well accepted that AMBS has institutional investors willing to take positions in a new NASDAQ kid on the block. Couple that with a successful Dx spin off, shelf offering and capital raise, things could get interesting quickly - something we all hope for, with some praying hard along the way....
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM